🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Upper Tract Urothelial Carcinoma

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma NCT05595408n/a1 site📍 Shanghai RenJi Hospital · Tests: Adjuvant chemotherapy, adjuvant immunotherapy Korean Prospective Upper Tract Urothelial Carcinoma Cohort NCT07452432n/a1 site📍 Seoul Samsung Medical Center · Tests: Peripheral blood collection for ctDNA analysis uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto NCT05874921n/a22 sites📍 Santa Monica📍 Gainesville📍 Miami UroGen Pharma Ltd. · Tests: Jelmyto (mitomycin) for pyelocalyceal solution Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs NCT06652022NA2 sites📍 Beijing📍 Beijing Peking University First Hospital · Tests: Systematic therapy combined with radiotherapy, Systematic drug treatment Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC NCT06598761n/a2 sites📍 Beijing📍 Beijing Peking University First Hospital · Tests: Immunotherapy+radiotherapy, surveillance alone Translational Cancer Observational Protocol NCT06169436n/a1 site📍 Milan IRCCS San Raffaele · Tests: Nephroureterectomy Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer NCT07673016n/a23 sites📍 Oceanside📍 San Diego📍 San Jose Convergent Genomics, Inc. Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC NCT07126119Phase 21 site📍 Tianjin Tianjin Medical University Second Hospital · Tests: Nab-Paclitaxel, Tislelizumab, Radical nephroureterectomy (RNU) Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma NCT06262516NA4 sites📍 Gainesville📍 Springfield📍 Cleveland Case Comprehensive Cancer Center · Tests: Nephroureterectomy, Lymph Node Dissection A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma NCT05917158Phase 21 site📍 Nanjing Jinling Hospital, China · Tests: RC48-ADC and JS001 Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer NCT07756437n/a1 site📍 Ghent AZ Sint-Lucas Gent POST URS Chemotherapy Instillation NCT06167057NA10 sites📍 Ashdod📍 Beersheba📍 Be’er Ya‘aqov Carmel Medical Center · Tests: Mitomycin/Gemcitabine, Saline Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial NCT06764095Phase 41 site📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Computed Tomography, Cystectomy, Enfortumab Vedotin, Local Therapy Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) NCT04574960Phase 32 sites📍 Ottawa📍 Toronto University Health Network, Toronto · Tests: Gemcitabine, Cisplatin, Carboplatin Flexible Ureterorenoscopy for Surveillance of Upper Tract Urothelial Carcinoma NCT07557563NA1 site📍 Hong Kong Chinese University of Hong Kong · Tests: Flexible ureterorenoscopy Prognosis of Patients With Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy NCT06204406n/a1 site📍 Shanghai RenJi Hospital · Tests: Observational Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer NCT05775471Phase 21 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Biopsy, Biospecimen Collection, Enfortumab Vedotin, MR Urography, Nephroureterectomy Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma NCT07265947Phase 232 sites📍 Loma Linda📍 Los Angeles📍 Tampa Tyra Biosciences, Inc · Tests: Dabogratinib (TYRA-300) 60mg, Dabogratinib (TYRA-300) 80mg Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA NCT06948552Phase 21 site📍 Detroit Henry Ford Health System · Tests: 5-Aminolevulinic acid Hydrochloride (Gliolan®) Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer NCT06356155Phase 22 sites📍 Ann Arbor📍 Philadelphia University of Michigan Rogel Cancer Center · Tests: Enfortumab vedotin, Pembrolizumab Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma NCT07498907Phase 31 site📍 Beijing Peking University First Hospital · Tests: Disitamab Vedotin (RC48), radiotherapy, Gemcitabine (1000 mg/m2), carboplatin SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma NCT06822010Phase 21 site📍 New Brunswick Rutgers, The State University of New Jersey · Tests: Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel) Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients NCT05912816Phase 21 site📍 Shanghai RenJi Hospital · Tests: RC48 Combined With Tislelizumab Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma NCT06124976Phase 2, Phase 38 sites📍 Vancouver📍 Winnipeg📍 Halifax Peter Black · Tests: ST-02 Liquid Biospy for Urinary Cancers NCT06116396n/a1 site📍 Milan IRCCS San Raffaele · Tests: Genetic analysis on isolated cells Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis NCT07614594n/a1 site📍 Zhengzhou Henan Provincial People's Hospital Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis NCT06668493Phase 1, Phase 29 sites📍 Scottsdale📍 Santa Monica📍 Jacksonville Ferring Pharmaceuticals · Tests: Nadofaragene Firadenovec Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC NCT07741448Phase 210 sites📍 Huanggang📍 Jingzhou📍 Shiyan Zhiquan Hu · Tests: Trastuzumab Rezetecan, Gemcitabine, Radical nephroureterectomy Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer NCT04628767Phase 2, Phase 3258 sites📍 Kingman📍 Fort Smith📍 Little Rock National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma NCT07630155NA1 site📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Analgesic Agent, Electronic Health Record Review, Lidocaine Topical, Medical Device Usage and Evaluation, Survey Admini…
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy